WS Investor
30 Apr 2026, 17:50
Bristol Myers Squibb Jumps 5% as Growth Portfolio Transition Gains Credibility
Bristol Myers Squibb shares are up 5% in trading on April 30, as a convincing Q1 2026 beat reassured investors that the company's transition away from legacy products is firmly on track.
Revenue came in at $11.49 billion, beating the $10.69 billion consensus by 7.4%, while adjusted EPS of $1.58 topped the $1.42 estimate by 11.1%. The driver was a clear and accelerating split between old and new: the Growth Portfolio, which now accounts for roughly 54% of total sales, delivered 12% revenue growth to $6.2 billion, led by Camzyos, Breyanzi and Reblozyl. International revenues rose 11%, contrasting with a 1% decline in US revenues, underscoring a shifting geographic mix as newer growth brands deliver double-digit gains worldwide. (Simply Wall St, IndexBox)
The legacy drag, while real, was anticipated. Legacy Portfolio revenues fell 6% to $5.3 billion as generic competition continued to erode older products, partly offset by a 16% rise in Eliquis worldwide sales to $4.1 billion. Non-GAAP EPS fell 12% year-on-year to $1.58, but management reaffirmed full-year guidance of $46 to $47.5 billion in revenue and $6.05 to $6.35 in non-GAAP EPS, noting that both metrics are trending toward the upper end of those ranges. (FinancialContent)
What is lifting the stock beyond the headline beat is the pipeline narrative. CEO Christopher Boerner pointed to multiple pivotal data readouts ahead, and the company has recently inked deals with Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics and Ajax Therapeutics, signaling aggressive expansion across oncology and beyond.
Bristol Myers Squibb shares are up 5% in trading on April 30, as a convincing Q1 2026 beat reassured investors that the company's transition away from legacy products is firmly on track.
Revenue came in at $11.49 billion, beating the $10.69 billion consensus by 7.4%, while adjusted EPS of $1.58 topped the $1.42 estimate by 11.1%. The driver was a clear and accelerating split between old and new: the Growth Portfolio, which now accounts for roughly 54% of total sales, delivered 12% revenue growth to $6.2 billion, led by Camzyos, Breyanzi and Reblozyl. International revenues rose 11%, contrasting with a 1% decline in US revenues, underscoring a shifting geographic mix as newer growth brands deliver double-digit gains worldwide. (Simply Wall St, IndexBox)
The legacy drag, while real, was anticipated. Legacy Portfolio revenues fell 6% to $5.3 billion as generic competition continued to erode older products, partly offset by a 16% rise in Eliquis worldwide sales to $4.1 billion. Non-GAAP EPS fell 12% year-on-year to $1.58, but management reaffirmed full-year guidance of $46 to $47.5 billion in revenue and $6.05 to $6.35 in non-GAAP EPS, noting that both metrics are trending toward the upper end of those ranges. (FinancialContent)
What is lifting the stock beyond the headline beat is the pipeline narrative. CEO Christopher Boerner pointed to multiple pivotal data readouts ahead, and the company has recently inked deals with Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics and Ajax Therapeutics, signaling aggressive expansion across oncology and beyond.